There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
BRIDGEWATER, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer, and Dr. Iain Stuart, Chief Scientific Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Autoimmune & In
VYNE Therapeutics ( NASDAQ:VYNE ) Full Year 2023 Results Key Financial Results Net loss: US$27.9m (loss narrowed by 18...